Cipla Ltd.

Cipla has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine Remdesivir, which has been issued an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (USFDA) to treat COVID-19 patients. This agreement is part of company’s efforts to enhance global access to lifesaving treatments for patients affected by the pandemic.

As part of the agreement, Cipla will be permitted to manufacture the API and Finished product, and market it in 127 countries including India and South Africa under company’s own brand name. The company will receive the manufacturing know-how from Gilead Sciences, Inc. to manufacture the API and Finished product at a commercial scale. The company’s extensive geographical and commercial footprint will help make this therapy accessible to more patients and markets.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.